Q1 2026 Kyntra Bio Inc Earnings Call Transcript
Key Points
- Kyntra Bio Inc (KYNB) is actively enrolling patients in a Phase 2 monotherapy trial for FG-3246 in metastatic castration-resistant prostate cancer, with an anticipated interim analysis in Q4 2026.
- The company has a cash runway into 2028, providing financial stability to continue investing in its pipeline.
- Roxadustat has received orphan drug designation for lower-risk myelodysplastic syndromes, with a Phase 3 trial expected to initiate in the second half of 2026.
- Kyntra Bio Inc (KYNB) reported an increase in total revenue to $3.7 million for Q1 2026, compared to $2.7 million in the same period of 2025.
- The company has reduced R&D and SG&A expenses compared to the previous year, indicating improved cost management.
- Kyntra Bio Inc (KYNB) reported a net loss of $15.1 million for Q1 2026, although this is an improvement from the previous year's loss.
- The company is not disclosing enrollment figures for its ongoing trials, which may concern investors seeking transparency.
- FG-3246's Phase 1 trial showed a median RPFS of 8.7 months, which the company aims to improve upon, indicating current results may not yet meet commercial competitiveness benchmarks.
- The company faces risks related to the development and regulatory approval of its clinical programs, as highlighted in their forward-looking statements.
- Kyntra Bio Inc (KYNB) is still in the process of finalizing the Phase 3 protocol for roxadustat, indicating potential delays in trial initiation.
Good day, and thank you for standing by. Welcome to the Kyntra Bio first-quarter 2026 earnings conference call. (Operator Instructions) Please be advised that today's call is being recorded.
I would now like to hand it over to our first speaker, Gaia Shamis. Please go ahead.
Thank you, Victor. Good afternoon, everyone, and thank you for joining us today to discuss Kyntra Bio's first-quarter 2026 financial and business results. I'm Gaia Shamis from LifeSci Advisors.
Joining me on today's calls are Thane Wettig, Chief Executive Officer; David DeLucia, Chief Financial Officer; and Carol Gaddum, Vice President of Product Development. Following the prepared remarks, we will open the call to your questions.
I would like to remind you that remarks made on today's call include forward-looking statements about Kyntra Bio. Such statements may include, but are not limited to, collaborations with AstraZeneca and Astellas; financial guidance; the initiation, enrollment, design, conduct, and
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
